-
1
-
-
5344234076
-
The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications
-
DOI 10.1016/j.ejca.2004.07.006, PII S0959804904005660
-
Burger AM and Seth AK: The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 40: 2217-2229, 2004. (Pubitemid 39348871)
-
(2004)
European Journal of Cancer
, vol.40
, Issue.15
, pp. 2217-2229
-
-
Burger, A.M.1
Seth, A.K.2
-
2
-
-
2342613652
-
The proteasome: A suitable antineoplastic target
-
Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360, 2004.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 349-360
-
-
Adams, J.1
-
3
-
-
47349102144
-
Effect of bortezomib on human neuroblastoma: Analysis of molecular mechanisms involved in cytotoxicity
-
Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R and Puisieux A: Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer 7: 50, 2008.
-
(2008)
Mol Cancer
, vol.7
, pp. 50
-
-
Combaret, V.1
Boyault, S.2
Iacono, I.3
Brejon, S.4
Rousseau, R.5
Puisieux, A.6
-
4
-
-
0142244338
-
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells
-
DOI 10.1038/sj.leu.2403109
-
Pei XY, Dai Y and Grant S: The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17: 2036-2045, 2003. (Pubitemid 37322135)
-
(2003)
Leukemia
, vol.17
, Issue.10
, pp. 2036-2045
-
-
Pei, X.-Y.1
Dai, Y.2
Grant, S.3
-
5
-
-
65449166841
-
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade
-
Yerlikaya A and Erin N: Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int J Mol Med 22: 817-823, 2008.
-
(2008)
Int J Mol Med
, vol.22
, pp. 817-823
-
-
Yerlikaya, A.1
Erin, N.2
-
6
-
-
26844452967
-
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
-
Boccadoro M, Morgan G and Cavenagh J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 5: 18, 2005.
-
(2005)
Cancer Cell Int
, vol.5
, pp. 18
-
-
Boccadoro, M.1
Morgan, G.2
Cavenagh, J.3
-
7
-
-
0034902354
-
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappaB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
-
Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P and Van Waes C: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7: 1419-1428, 2001. (Pubitemid 32708698)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.5
, pp. 1419-1428
-
-
Sunwoo, J.B.1
Chen, Z.2
Dong, G.3
Yeh, N.4
Bancroft, C.C.5
Sausville, E.6
Adams, J.7
Elliott, P.8
Van Waes, C.9
-
8
-
-
0036735298
-
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model
-
LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000, 2002. (Pubitemid 34984425)
-
(2002)
Cancer Research
, vol.62
, Issue.17
, pp. 4996-5000
-
-
LeBlanc, R.1
Catley, L.P.2
Hideshima, T.3
Lentzsch, S.4
Mitsiades, C.S.5
Mitsiades, N.6
Neuberg, D.7
Goloubeva, O.8
Pien, C.S.9
Adams, J.10
Gupta, D.11
Richardson, P.G.12
Munshi, N.C.13
Anderson, K.C.14
-
9
-
-
6344229760
-
Proteasome inhibition sensitizes nonsmall cell lung cancer to histone deacetylase inhibitorinduced apoptosis through the generation of reactive oxygen species
-
DOI 10.1016/j.jtcvs.2004.07.010, PII S0022522304009857
-
Denlinger CE, Rundall BK and Jones DR: Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128: 740-748, 2004. (Pubitemid 39388930)
-
(2004)
Journal of Thoracic and Cardiovascular Surgery
, vol.128
, Issue.5
, pp. 740-748
-
-
Denlinger, C.E.1
Rundall, B.K.2
Jones, D.R.3
-
10
-
-
0032885416
-
The proteasome inhibitor PS-341 in cancer therapy
-
Teicher BA, Ara G, Herbst R, Palombella VJ and Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5: 2638-2645, 1999. (Pubitemid 29437352)
-
(1999)
Clinical Cancer Research
, vol.5
, Issue.9
, pp. 2638-2645
-
-
Teicher, B.A.1
Ara, G.2
Herbst, R.3
Palombella, V.J.4
Adams, J.5
-
12
-
-
77955275936
-
Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells
-
Chua BT, Lim SJ, Tham SC, Poh WJ and Ullrich A: Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells. Mol Oncol 4: 323-334, 2010.
-
(2010)
Mol Oncol
, vol.4
, pp. 323-334
-
-
Chua, B.T.1
Lim, S.J.2
Tham, S.C.3
Poh, W.J.4
Ullrich, A.5
-
13
-
-
84868091512
-
The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib
-
Yerlikaya A, Okur E and Ulukaya E: The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour Biol 33: 1385-1392, 2012.
-
(2012)
Tumour Biol
, vol.33
, pp. 1385-1392
-
-
Yerlikaya, A.1
Okur, E.2
Ulukaya, E.3
-
14
-
-
30544432958
-
BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53
-
DOI 10.1007/s11373-005-9025-y
-
Basma H, El-Refaey H, Sgagias MK, Cowan KH, Luo X and Cheng PW: BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. J Biomed Sci 12: 999-1011, 2005. (Pubitemid 43081679)
-
(2005)
Journal of Biomedical Science
, vol.12
, Issue.6
, pp. 999-1011
-
-
Basma, H.1
El-Refaey, H.2
Sgagias, M.K.3
Cowan, K.H.4
Luo, X.5
Cheng, P.-W.6
-
15
-
-
33746437215
-
Transcriptional profiling of MCF7 breast cancer cells in response to 5-flouracil: Relationship with cell cycle changes and apoptosis, and identification of novel targets of p53
-
DOI 10.1002/ijc.21938
-
Hernandez-Vargas H, Ballestar E, Carmona-Saez P, von Kobbe C, Banon-Rodriguez I, Esteller M, Moreno-Bueno G and Palacios J: Transcriptional profiling of MCF7 breast cancer cells in response to 5-fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer 119: 1164-1175, 2006. (Pubitemid 44121416)
-
(2006)
International Journal of Cancer
, vol.119
, Issue.5
, pp. 1164-1175
-
-
Hernandez-Vargas, H.1
Ballestar, E.2
Carmona-Saez, P.3
Von Kobbe, C.4
Banon-Rodriguez, I.5
Esteller, M.6
Moreno-Bueno, G.7
Palacios, J.8
-
16
-
-
78149456914
-
Antioxidant-prooxidant properties of a new organoselenium compound library
-
Plano D, Baquedano Y, Ibanez E, Jimenez I, Palop JA, Spallholz JE and Sanmartin C: Antioxidant-prooxidant properties of a new organoselenium compound library. Molecules 15: 7292-7312, 2010.
-
(2010)
Molecules
, vol.15
, pp. 7292-7312
-
-
Plano, D.1
Baquedano, Y.2
Ibanez, E.3
Jimenez, I.4
Palop, J.A.5
Spallholz, J.E.6
Sanmartin, C.7
-
17
-
-
4444311881
-
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity
-
Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D and Neckers L: Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 3: 551-566, 2004. (Pubitemid 39193734)
-
(2004)
Molecular Cancer Therapeutics
, vol.3
, Issue.5
, pp. 551-566
-
-
Mimnaugh, E.G.1
Xu, W.2
Vos, M.3
Yuan, X.4
Isaacs, J.S.5
Bisht, K.S.6
Gius, D.7
Neckers, L.8
|